Ardelyx 将来の成長

Future 基準チェック /66

Ardelyx利益と収益がそれぞれ年間69.6%と25.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に52.7% 69.5%なると予測されています。

主要情報

69.6%

収益成長率

69.5%

EPS成長率

Biotechs 収益成長	27.6%
収益成長率	25.5%
将来の株主資本利益率	52.7%
アナリストカバレッジ	Good
最終更新日	04 Dec 2024

今後の成長に関する最新情報

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 03

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 04

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04

Recent updates

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Oct 24

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Aug 25

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 07

Ardelyx Faces Rising Challenges Despite Revenue Growth

Aug 05

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 04

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Jul 13

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Jul 05

Ardelyx: Strong Execution, Fairly Valued

May 10

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

May 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Apr 17

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Mar 13

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Feb 20

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Jan 31

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Jan 10

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Jan 04

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Dec 14

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 03

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Jul 31

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Apr 17

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Mar 30

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Dec 14

業績と収益の成長予測

NasdaqGM:ARDX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	550	113	160	165	9
12/31/2025	401	-24	57	42	10
12/31/2024	326	-42	N/A	-21	10
9/30/2024	252	-73	-64	-63	N/A
6/30/2024	210	-65	-86	-85	N/A
3/31/2024	159	-66	-81	-81	N/A
12/31/2023	124	-66	-90	-90	N/A
9/30/2023	134	-27	-67	-67	N/A
6/30/2023	83	-56	-71	-71	N/A
3/31/2023	63	-66	-87	-87	N/A
12/31/2022	52	-67	-70	-70	N/A
9/30/2022	9	-114	-124	-124	N/A
6/30/2022	5	-135	-133	-133	N/A
3/31/2022	4	-153	-137	-136	N/A
12/31/2021	10	-158	-154	-153	N/A
9/30/2021	11	-151	-133	-131	N/A
6/30/2021	12	-125	-118	-116	N/A
3/31/2021	13	-105	-102	-101	N/A
12/31/2020	8	-94	-82	-81	N/A
9/30/2020	8	-85	-75	-75	N/A
6/30/2020	8	-91	-76	-76	N/A
3/31/2020	6	-91	-85	-85	N/A
12/31/2019	5	-95	-77	-76	N/A
9/30/2019	3	-103	-84	-84	N/A
6/30/2019	0	-104	-91	-90	N/A
3/31/2019	0	-100	-81	-80	N/A
12/31/2018	3	-91	-71	-70	N/A
9/30/2018	45	-53	-47	-47	N/A
6/30/2018	44	-50	N/A	-39	N/A
3/31/2018	44	-53	N/A	-45	N/A
12/31/2017	42	-64	N/A	-65	N/A
9/30/2017	N/A	-106	N/A	-97	N/A
6/30/2017	N/A	-114	N/A	-102	N/A
3/31/2017	N/A	-117	N/A	-103	N/A
12/31/2016	N/A	-112	N/A	-93	N/A
9/30/2016	N/A	-98	N/A	-87	N/A
6/30/2016	N/A	-87	N/A	-75	N/A
3/31/2016	18	-50	N/A	-80	N/A
12/31/2015	24	-30	N/A	-72	N/A
9/30/2015	30	-16	N/A	-54	N/A
6/30/2015	38	2	N/A	-48	N/A
3/31/2015	29	-6	N/A	6	N/A
12/31/2014	32	-3	N/A	13	N/A
9/30/2014	34	-4	N/A	28	N/A
6/30/2014	33	-5	N/A	34	N/A
3/31/2014	31	-7	N/A	5	N/A
12/31/2013	29	-7	N/A	2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ARDXは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: ARDX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ARDX今後 3 年以内に収益を上げることが予想されます。

収益対市場: ARDXの収益 ( 25.5% ) US市場 ( 9.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: ARDXの収益 ( 25.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ARDXの自己資本利益率は、3年後には非常に高くなると予測されています ( 52.7 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/26 18:07
終値	2024/12/24 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Ardelyx, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。17

アナリスト	機関
Timothy Chiang	BTIG
Mara Goldstein	Cantor Fitzgerald & Co.
Louise Chen	Cantor Fitzgerald & Co.

Ardelyx 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Consensus revenue estimates increase by 18%

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date pushed back to 2026

Price target increased by 7.1% to US$13.39

Recent updates

Ardelyx: A Small Bet Its Latest Setback Will Be Temporary

Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It

Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Ardelyx, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week

Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Ardelyx Faces Rising Challenges Despite Revenue Growth

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Ardelyx, Inc. Announces Publication of Two Plain Language Summaries from XPHOZAH®? (tenapanor) Clinical Trials in Current Medical Research and Opinion

Ardelyx, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index

Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

President recently sold US$246k worth of stock

Insider recently sold US$782k worth of stock

Ardelyx: Strong Execution, Fairly Valued

Consensus revenue estimates increase by 18%

Insider notifies of intention to sell stock

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2026

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

President notifies of intention to sell stock

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Price target increased by 7.1% to US$13.39

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Insider notifies of intention to sell stock

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Ardelyx, Inc. announced that it has received $50 million in funding

Consensus EPS estimates fall by 95%, revenue upgraded

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS misses analyst expectations

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Consensus estimates of losses per share improve by 10%

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Key Executive notifies of intention to sell stock

Price target increased by 9.5% to US$9.94

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Insider notifies of intention to sell stock

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States

Consensus revenue estimates increase by 16%

Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023

Price target increased by 10% to US$9.36

Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Insufficient new directors

Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023

Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor

Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

Consensus revenue estimates increase by 17%

New major risk - Shareholder dilution

Price target increased by 7.1% to US$7.58

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations